Market Overview

Why Inhibrx's Stock Is Trading Higher Today


Inhibrx (NASDAQ: INBX) shares are trading higher on Monday after multiple firms initiated coverage on the stock with a bullish rating.

Inhibrx is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates.

Inhibrx shares were trading up 6.49% at $8.21 on Monday during the time of publication. The stock has a 52-week high of $26.98 and a 52-week low of $15.76.

Latest Ratings for INBX

Sep 2020JefferiesInitiates Coverage OnBuy
Sep 2020Evercore ISI GroupInitiates Coverage OnOutperform
Sep 2020Credit SuisseInitiates Coverage OnOutperform

View More Analyst Ratings for INBX
View the Latest Analyst Ratings


Related Articles (INBX)

View Comments and Join the Discussion!

Posted-In: why it's movingInitiation Analyst Ratings

Latest Ratings

CMGDeutsche BankMaintains1,235.0
AAPLPiper SandlerMaintains135.0
ALGNPiper SandlerMaintains500.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at